Combination of NA49 with Gef in EGFR-WT and Mut cells or with cisplatin in EGFR-WT cells synergistically induced combination effects to NSCLC cell lines, suggesting NA49 as a universal combination treatment candidate to combat HSP27-mediated resistance. Here, EGFR is linked to non-small cell lung carcinoma.